Recombinant TAT-gelonin fusion toxin: Synthesis and characterization of heparin/protamine-regulated cell transduction

Journal of Biomedical Materials Research - Part A

Volumn 103, Issue 1, 2015, Pages 409-419

  Shin, Meong Cheol ^a,b   Zhao, Jingwen ^c   Zhang, Jian ^d   Huang, Yongzhuo ^e   He, Huining ^a   Wang, Mei ^f   Min, Kyoung Ah ^b   Yang, Victor C ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MICHIGAN   (United States)

^c TIANJIN UNIVERSITY   (China)

^d SOOCHOW UNIVERSITY   (China)

^e SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^f XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

gelonin; heparin; protamine; TAT; tumor

Indexed keywords

BACTERIOPHAGES; CELL CULTURE; CELL MEMBRANES; CYTOTOXICITY; DISEASES; DRUG THERAPY; POLYSACCHARIDES; SYNTHESIS (CHEMICAL); TUMORS;

GELONIN; GENETIC RECOMBINATIONS; HEPARIN; N-GLYCOSIDASE ACTIVITIES; PROTAMINE; PROTEIN TRANSDUCTION DOMAINS; SYNTHESIS AND CHARACTERIZATIONS; TAT;

RECOMBINANT PROTEINS;

GELONIN; GLYCOSIDASE; HEPARIN; HYBRID PROTEIN; PROTAMINE SULFATE; RECOMBINANT TAT GELONIN FUSION PROTEIN; UNCLASSIFIED DRUG; GEL PROTEIN, GELONIUM MULTIFLORUM; PROTAMINE; RIBOSOME INACTIVATING PROTEIN 1; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG SYNTHESIS; GENETIC ENGINEERING; GENETIC RECOMBINATION; IC50; IN VITRO STUDY; IN VIVO STUDY; ION EXCHANGE CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; RETICULOCYTE LYSATE; SIGNAL TRANSDUCTION; TUMOR VOLUME; ANIMAL; CELL LINE; CHEMISTRY; GENETIC TRANSDUCTION; HUMAN;

ANIMALS; CELL LINE; GENE PRODUCTS, TAT; HEPARIN; HUMANS; PROTAMINES; RECOMBINANT FUSION PROTEINS; RIBOSOME INACTIVATING PROTEINS, TYPE 1; TRANSDUCTION, GENETIC;

EID: 84912572825     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.35188     Document Type: Article

References (35)

1. Antignani A, Fitzgerald D,. Immunotoxins: The role of the toxin. Toxins 2013; 5: 1486-1502.
2. Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, Goekbuget N, Schrappe M, Pui CH,. L-asparaginase treatment in acute lymphoblastic leukemia: A focus on Erwinia asparaginase. Cancer 2011; 117: 238-249.
3. Cheng PN, Lam TL, Lam WM, Tsui SM, Cheng AW, Lo WH, Leung YC,. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res 2007; 67: 309-317.
4. Pastan I, FitzGerald D,. Recombinant toxins for cancer treatment. Science 1991; 254: 1173-1177.
5. Pasut G, Sergi M, Veronese FM,. Anti-cancer PEG-enzymes: 30 years old, but still a current approach. Adv Drug Deliv Rev 2008; 60: 69-78.
6. Stirpe F, Olsnes S, Pihl A,. Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A. J Biol Chem 1980; 255: 6947-6953.
7. Puri M, Kaur I, Perugini MA, Gupta RC,. Ribosome-inactivating proteins: Current status and biomedical applications. Drug Discov Today 2012; 17: 774-783.
8. Atkinson SF, Bettinger T, Seymour LW, Behr JP, Ward CM,. Conjugation of folate via gelonin carbohydrate residues retains ribosomal-inactivating properties of the toxin and permits targeting to folate receptor positive cells. J Biol Chem 2001; 276: 27930-27935.
9. Shin MC, Zhang J, David AE, Trommer WE, Kwon YM, Min KA, Kim JH, Yang VC,. Chemically and biologically synthesized CPP-modified gelonin for enhanced anti-tumor activity. J Control Release 2013; 172: 169-178.
10. Borthakur G, Rosenblum MG, Talpaz M, Daver N, Ravandi F, Faderl S, Freireich EJ, Kadia T, Garcia-Manero G, Kantarjian H, Cortes JE,. Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica 2013; 98: 217-221.
11. Cao Y, Marks JW, Liu Z, Cheung LH, Hittelman WN, Rosenblum MG,. Design optimization and characterization of Her2/neu-targeted immunotoxins: Comparative in vitro and in vivo efficacy studies. Oncogene 2014; 33: 429-439.
12. Goldmacher VS, Scott CF, Lambert JM, McIntyre GD, Blattler WA, Collnhson AR, Stewart JK, Chong LD, Cook S, Slayter HS, Beaumont E, Watkins S,. Cytotoxicity of gelonin and its conjugates with antibodies is determined by the extent of their endocytosis. J Cell Physiol 1989; 141: 222-234.
13. Pirie CM, Liu DV, Wittrup KD,. Targeted cytolysins synergistically potentiate cytoplasmic delivery of gelonin immunotoxin. Mol Cancer Ther 2013; 12: 1774-1782.
14. Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, Marks JD, Adams GP,. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res 2011; 71: 2250-2259.
15. Shin MC, Zhang J, Min KA, Lee K, Byun Y, David AE, He H, Yang VC,. Cell-penetrating peptides: Achievements and challenges in application for cancer treatment. J Biomed Mater Res A 2014; 102: 575-587.
16. Bechara C, Sagan S,. Cell-penetrating peptides: 20 years later, where do we stand? FEBS Lett 2013; 587: 1693-1702.
17. Huang Y, Jiang Y, Wang H, Wang J, Shin MC, Byun Y, He H, Liang Y, Yang VC,. Curb challenges of the "Trojan Horse" approach: Smart strategies in achieving effective yet safe cell-penetrating peptide-based drug delivery. Adv Drug Deliv Rev 2013; 65: 1299-1315.
18. He H, Ye J, Wang Y, Liu Q, Chung HS, Kwon YM, Shin MC, Lee K, Yang VC,. Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application. J Control Release 2013; 176: 123-132.
19. Lee JY, Choi YS, Suh JS, Kwon YM, Yang VC, Lee SJ, Chung CP, Park YJ,. Cell-penetrating chitosan/doxorubicin/TAT conjugates for efficient cancer therapy. Int J Cancer 2011; 128: 2470-2480.
20. Li YT, Kwon YM, Spangrude GJ, Liang JF, Chung HS, Park YJ, Yang VC,. Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy. J Biomed Mater Res A 2009; 91: 209-220.
21. Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY,. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci USA 2004; 101: 17867-17872.
22. Jiang T, Zhang Z, Zhang Y, Lv H, Zhou J, Li C, Hou L, Zhang Q,. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. Biomaterials 2012; 33: 9246-9258.
23. Kwon YM, Li YT, Liang JF, Park YJ, Chang LC, Yang VC,. PTD-modified ATTEMPTS system for enhanced asparaginase therapy: A proof-of-concept investigation. J Control Release 2008; 130: 252-258.
24. Hossann M, Li Z, Shi Y, Kreilinger U, Buttner J, Vogel PD, Yuan J, Wise JG, Trommer WE,. Novel immunotoxin: A fusion protein consisting of gelonin and an acetylcholine receptor fragment as a potential immunotherapeutic agent for the treatment of Myasthenia gravis. Protein Expr Purif 2006; 46: 73-84.
25. Lindgren M, Hallbrink M, Prochiantz A, Langel U,. Cell-penetrating peptides. Trends Pharmacol Sci 2000; 21: 99-103.
26. Jiao CY, Delaroche D, Burlina F, Alves ID, Chassaing G, Sagan S,. Translocation and endocytosis for cell-penetrating peptide internalization. J Biol Chem 2009; 284: 33957-33965.
27. Lee TY, Park YS, Garcia GA, Sunahara RK, Woods JH, Yang VC,. Cell permeable cocaine esterases constructed by chemical conjugation and genetic recombination. Mol Pharm 2012; 9: 1361-1373.
28. Kane JF,. Effects of rare codon clusters on high-level expression of heterologous proteins in Escherichia coli. Curr Opin Biotechnol 1995; 6: 494-500.
29. LaVallie ER, DiBlasio-Smith EA, Collins-Racie LA, Lu Z, McCoy JM,. Thioredoxin and related proteins as multifunctional fusion tags for soluble expression in E. coli. Methods Mol Biol 2003; 205: 119-140.
30. Li Z, Qu Y, Li H, Yuan J,. Truncations of gelonin lead to a reduction in its cytotoxicity. Toxicology 2007; 231: 129-136.
31. Console S, Marty C, Garcia-Echeverria C, Schwendener R, Ballmer-Hofer K,. Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J Biol Chem 2003; 278: 35109-35114.
32. Yuan X, Lin X, Manorek G, Howell SB,. Challenges associated with the targeted delivery of gelonin to claudin-expressing cancer cells with the use of activatable cell penetrating peptides to enhance potency. BMC Cancer 2011; 11: 61.
33. Calnan BJ, Tidor B, Biancalana S, Hudson D, Frankel AD,. Arginine-mediated RNA recognition: The arginine fork. Science 1991; 252: 1167-1171.
34. Eiklid K, Olsnes S, Pihl A,. Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells. Exp Cell Res 1980; 126: 321-326.
35. Brooks H, Lebleu B, Vives E,. Tat peptide-mediated cellular delivery: Back to basics. Adv Drug Deliv Rev 2005; 57: 559-577.